Abstract. In the present study, we analyzed differential composition of blood serum from Ehrlich carcinoma-bearing and healthy male C57Bl/6 mice by isolating complexes of hemoglobin and other serum proteins by a proteomic approach (gel filtration, gel electrophoresis, and mass spectrometry). The hemoglobin fractions isolated from the serum of micebearing tumors contained several proteins with molecular weights of 15, 65, 68, and 100 kDa, while hemoglobin fractions isolated from the serum of healthy mice did not contain additional protein bands. These bands were identified by MALDI-TOF as haptoglobin, serum albumin, a homologue of α-fetoprotein, and hemoglobin-α. Ion exchange chromatography indicated complex formation of these proteins. Injection of hemoglobin-associated blood serum proteins (HAP) isolated from tumor-bearing animals, leads to tumor regression. Intraperitoneally injected HAP-induced apoptosis in Ehrlich carcinoma cells but not normal peritoneal cells and led to a complete regression of the ascitic or solid Ehrlich carcinoma. A one-year follow up of the animals did not reveal any signs of tumor growth. In conclusion, HAP might be a novel principle of tumor regression. The clinical relevance of these findings with Ehrlich carcinoma should be investigated in the future.
Introduction
The immune and humoral systems play eminent roles for cell to cell or cell to organ communication in higher organisms. Aberrant signaling in both systems causes diseases. The link between these two signaling routes and cancer has been a matter of research for many years. Despite considerable progress, the understanding of the interplay between normal defense mechanisms of the body and tumor growth is still incomplete. It is known for many decades that the surgical removal of a primary tumor can stimulate the growth of distant metastases (1) . It was postulated that growth factors present in blood serum could mediate this effect. The transfer of serum from tumor-bearing animals accelerates metastatic tumor growth in recipient mice (1) . In contrast, other investigators found that the transfer of tumor-sensitized cells from one tumor-bearing subject to another confers protection against tumor growth (2) (3) (4) . While the latter line of research led to modern immunotherapy concepts of adoptive immunotherapy using cytotoxic T-cells (5) , the role of serum factors for tumor growth was not developed with the same intensity during the past years.
In our own studies, we showed that surgical removal of Ehrlich carcinoma does not entail a longer survival time of CBA C57Bl/6 mice compared to non-operated tumor-bearing mice (6) . While operation of tumors was followed by the development of metastases in 100% of the animals, metastases were not observed in non-operated tumor-bearing mice. Surprisingly, repeated transplantation of tumor cells (second challenge) did not result in tumor development in operated mice despite metastatic growth derived from the first challenge with tumor cells. This suggests that metastatic growth as well as suppression of second challenge tumors depend on factors present in the blood serum of the host organisms.
While we did not identify specific serum proteins responsible for these effects (6, 7) , the data of others point to serum proteins, which could affect tumor growth. The transgenic mice strain MMTV-neu (ErbB-2) with transplanted breast cancer showed that the liver of tumor-bearing mice displayed a fetal phenotype with expression of α-fetoprotein (AFP) (8) . AFP acts as a growth factor and biological response modifier, which affects cell proliferation (9) (10) (11) (12) . AFP functions as a transporter of various ligands, such as steroid hormones and hemoglobin degradation products (bilirubin) (13) (14) (15) . Ivanov et al (16, 17) reported that peptides resulting from hemoglobin degradation products affect tumor cell proliferation.
In the present study, we analyzed the differential composition of blood serum from Ehrlich carcinoma-bearing and healthy mice by isolating hemoglobin-associated serum proteins using a proteomic approach (gel filtration, gel electrophoresis, and mass spectrometry). The biological activity of these proteins was analyzed regarding apoptosis and anti-tumor effect in vivo.
Materials and methods
Tumor and animal experimentation. Ascitic Ehrlich carcinoma (aneuploid strain ELD) was obtained from the bank of tumor strains of the N.N. Blokhin Russian Cancer Research Center (Moscow, Russia). Cells were transplanted intraperitoneally (i.p.) to obtain ascitic tumors or by intramuscular injection (i.m.) to obtain solid tumors into the right hind limb of C57Bl/6 mice (1x10 6 cells/mouse diluted in 100 μl RPMI-1640 medium, Panecko, Russia). The experiments were carried out using male, 2-3 months old C57Bl/6 mice. The animals were obtained from Stolbovaya Company (Moscow, Russia). The mice received standard laboratory feeding and tap water ad libitum. All experiments were done in accordance with the legal regulations for animal experimentation in Russia and with official permission of the Institute of Experimental Diagnosis and Therapy of Tumors of the N.N. Blokhin Russian Cancer Research Center (18) .
To determine the effect of blood serum from tumor-bearing mice, we administered hemoglobin-associated proteins and serum proteins of tumor-bearing or blood serum from healthy mice (100 μg/mouse in 400 μl 0.9% NaCl solution) to other mice bearing i.p. or i.m. transplanted Ehrlich carcinoma cells. The administration was performed i.p. four days after tumor transplantation and repeated 5 times at intervals of 48 h. Each group included 10 animals. Statistical evaluation was done using Fisher's Student test. Difference was reliable with p<0.05.
Protein isolation. Hemoglobin-associated proteins (HAP) were isolated from the blood of mice bearing i.m. transplanted Ehrlich carcinoma, after the tumors reached a size of >1 cm 3 . Serum was diluted in 0.01 M Tris buffer (pH 7.4, 0.01% sodium azide), transferred on PD-10 columns (Amersham Biosciences, Freiburg, Germany), and left for 12 h at 4˚C. The precipitate was separated by centrifugation at 1000 x g for 20 min. Proteins were applied to Sephadex QFF columns. Non-bound serum proteins were eluated by 0.01 M Tris buffer, pH 7.4, with 0.01% sodium azide, while the bound proteins were eluated by a sodium chloride gradient (0.5 M, 0.01 M Tris buffer, pH 7.4, with 0.01% sodium azide) with the help of a GP-250 programmed gradient pump (Pharmacia). Protein elution was monitored in a flow cell at λ=280 nm. The redcolored hemoglobin eluate was monitored visually, and an aliquot was measured at HP 8452 A diode array spectrophotometer and absorption value of λ=414 nm. The isolated hemoglobin complexes were subjected to HW-55F columns (Tosoh Bioscience, Stuttgart, Germany), and the red-stained aliquots were collected. HW-55F columns (26x56 cm) were calibrated by proteins (urease, catalase, γ-globulin, albumin, cytochrom c) for detection weight of proteins in eluate. The separation of protein fractions was performed by ion exchange chromatography by Sephadex QFF columns, gel filtration with HW-55F columns, and SDS electrophoresis. MALDI-TOF-mass spectrometry (19) was used for identification of proteins associated with hemoglobin.
Protein gel electrophoresis. Proteins samples were separated by SDS/PAGE on a 12.5% gel and stained with Coomassie Blue according to Laemmli (20) . Samples subjected to SDS/ PAGE were solubilized in sample buffer, containing 63 mM Tris/HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, and 30 μM bromophenol blue. 2-Mercaptoethanol 5% (v/v) was conditionally added to or omitted in the sample buffer. Unless stated otherwise, 12.5% acrylamide gels, with a bisacrylamide/ acrylamide ratio of 0.8:30, were used. Samples were applied in quantities of 20 μg protein/lane to evaluate all components of protein complexes.
MALDI-TOF.
Protein strips were cut out from electrophoresis gels, using a Proteome Works spot picking robot (Bio-Rad Laboratories, Hercules, CA, USA). Trypsin-type proteasecleaved peptides were used in the peptide mixtures. Mass spectra were received by means of MALDI-TOF Reflex III mass spectrometers (Bruker, BioSciences, Billerica, MA, USA) equipped with UV laser (336 nm). The range of positive ions was recorded from 500 up to 8000 Da. of ascitic liquid was aspirated and centrifuged at 800 μg in physiological solution for 10 min. Ascites was fixed in 70% ethyl alcohol and stored at -20˚C. The cells were re-suspended in physiological solution. Normal peritoneal cells were treated in the same way and used as a control.
For staining, propidium iodide (Sigma, Deisenhofen, Germany) was added at a final concentration of 1 μg/ml. Flow cytometry results were obtained from 10,000 cells collected in the gate set by combination of forward and side light scatters. The results were analyzed by means of the WINMDI 2.8 software.
For annexin V staining, cells were harvested and washed in physiological solution. Then, 1x10 6 cells were incubated with FITC-labeled annexin V (AnnexinV kit; Caltag Laboratories/ Invitrogen, Carlsbad, CA, USA) and propidium iodide (1 μg/ ml) for 15 min at room temperature and subjected to flow cytometry as described above.
DNA fragmentation assay. Ascitic Ehrlich carcinoma cells were taken from mice and washed 3 times and resuspended in physiological solution. In control groups, normal peritoneal cells from healthy mice were washed and re-suspended in physiological solution. DNA was extracted according to a previously described protocol, subjected to 1% agarose gel electrophoresis, and stained with 1 μg/ml ethidium bromide (Sigma) (21).
Results
We transplanted mice i.m. with Ehrlich carcinoma cells. After the tumors reached a size of ~1 cm 3 , the animals were sacrificed and blood serum was taken. In parallel, the serum of non-transplanted healthy mice was taken as control. Each group contained 10 animals. In Fig. 1 , the elution profiles of hemoglobin from blood serum of healthy and tumor-bearing mice after ion exchange chromatography with Sephadex QFF columns are shown. Hemoglobin of healthy animals was eluted with in a total volume of 10 (±1) ml (Fig. 1A) , whereas the volume required eluting hemoglobin from tumor-bearing mice was 160 (±3) ml (Fig. 1B) . This indicates either a change of charge of hemoglobin or formation of hemoglobin complexes.
Then, we separated proteins from Ehrlich carcinomabearing and healthy control mice by gel filtration with HW-55F columns. Hemoglobin of tumor-bearing mice was eluted in a volume of 155 (±5) ml (n=10), whereas hemoglobin of healthy animals was eluted in 190 (±5) ml (n=10), indicating that proteins or associations of proteins of different molecular size were present in the samples from tumor-bearing and healthy mice. The elution volumes corresponded to proteins with molecular weights of 60 and 310 kDa, respectively. The proteins identified had different optical densities at λ=280 nm and λ=414 nm in spectrophotometry (Fig. 2) .
To study the proteins of the blood sera, we performed gel electrophoresis (Fig. 3) . The hemoglobin fractions isolated from the serum of the healthy mice contained protein bands at 15 kDa, a double band at 30 kDa and a faint double band at 45 kDa (Fig. 3, lane 1) . The hemoglobin fractions isolated from the serum of mice bearing tumors contained several proteins with molecular weights of 15, 65, and 68-100 kDa (Fig. 3, lane 2) . Since high molecular weight proteins such as haptoglobin can associate with other proteins to form complexes of various molecular weight (22) , which could be dissociated in standard sample buffer containing 2-mercaptoethanol, we also used sample buffer without 2-mercaptoethanol for protein samples of mice bearing Ehrlich carcinoma. Whereas 2-mercaptoethanol-free protein samples contained protein bands of ~310 kDa (Fig. 3, lane 3) indicative for protein complexes, these bands were not visible in 2-mercaptoethanol containing protein samples (Fig. 3, lane 2) . Instead, several smaller bands between 50 and 300 kDa appeared indicating that the high molecular weight complexes are broken.
To identify the proteins in the sera of tumor-bearing mice found gel electrophoresis, we applied MALDI-TOF MS analysis. The double band with a molecular weight of ~15 kDa was identified as hemoglobin-α. The 65 kDa band was noted as gi|26341396 unknown protein (Mus musculus) with homology to α-fetoprotein. The band at 68 kDa was found to be serum albumin, and the 100 kDa band was identified as haptoglobin (Table I) . Probability based mowse score MALDI-TOF spectra for serum protein are shown in Fig. 4 . The double band of 30 kDa in serum of healthy mice, which was only faint in serum of tumor-bearing mice, was identified Ions score is -10*Log(P), where P is the probability that the observed match is a random event. Protein scores >67 are significant (p<0.05). This experiment was repeated 3 times.
as dimeric hemoglobin. The thin bands of 45 kDa in serum of healthy mice represent trimeric hemoglobin.
To investigate functional aspects of these serum components, we injected HAP i.p. from tumor-bearing mice into recipient mice, which carried ascitic Ehrlich carcinoma cells, and performed flow cytometric measurements (Fig. 5) . In tumor-bearing mice without HAP injection, Ehrlich carcinoma cells were highly proliferating with a large portion of cells in the S/G2/M cell cycle phases. As the ELD strain of Ehrlich carcinoma is aneuploid with two different stem lines, it was difficult to dissect the different cell cycle phase to determine the percentage of their cell cycle fractions (Fig. 5A) . The fraction of sub-G1 Ehrlich carcinoma cells was 2.8±0.5% in mice without HAP inoculation (n=3). Upon HAP injection, the fraction of proliferating cells decreased, and 33.4±1.1% of tumor cells appeared in the sub-G1 fraction indicating tumor cell death (Fig. 5B ). For control, 50 μl blood serum of healthy mice was injected into tumor-bearing mice, and no increase of the sub-G1 fraction of Ehrlich carcinoma cells was observed.
Then, we analyzed diploid normal peritoneal cells by flow cytometry. Normal peritoneal cells from mice inoculated with or without HAP did not undergo apoptosis indicating that HAP are inactive against normal peritoneal cells (Fig. 5C  and D) . Hence, normal peritoneal cells can serve as a negative control for the specificity of the reaction of HAP against tumor cells. Furthermore, normal peritoneal cells did not show a growth fraction (S/G2/M cells).
The results of the propidium iodide staining indicated that HAP injection induces apoptosis in ascitic Ehrlich carcinoma cells, but not in normal peritoneal cells. To prove this in more detail, we applied annexin-V staining and flow cytometry. As shown in Fig. 6 , 37.2% ascitic Ehrlich carcinoma cells were apoptotic after HAP injection (Fig. 6B) , whereas only 0.4% apoptotic cells were found in untreated ascitic Ehrlich carcinoma control cells (Fig. 6A ). For control, 50 μl blood serum of healthy mice was injected into tumor-bearing mice. No increase of the apoptotic fraction of ascitic Ehrlich carcinoma cells was observed compared to untreated mice. Furthermore, HAP injection did not lead to apoptosis induction in normal peritoneal cells compared to untreated peritoneal cells ( Fig. 6C and D) .
Furthermore, we investigated apoptosis by means of a DNA fragmentation assay. Typical apoptosis-associated DNA laddering was only found in HAP-treated ascitic Ehrlich carcinoma cells (Fig. 6E, lane 2) , but not in untreated ascitic Ehrlich carcinoma cells (Fig. 6E, lane 1) nor in untreated and HAP-treated normal peritoneal cells (Fig. 6E, lanes 3 and 4) .
As found by microscopic analysis, application of HAP to mice increased the size of ascitic Ehrlich carcinoma cells and induced vacuolization (Fig. 7A and B) . The size of peritoneal cells was not changed by HAP injection, and vacuolization was not present in these cells (Fig. 7C and D) .
We assessed the role of HAP for the regulation of tumor growth in vivo. HAP injection to mice with i.p. transplanted Table I . MALDI-TOF-mass spectrometry of proteins forming a complex with hemoglobin. --------------------------------------------------------------------------------------------------- Ehrlich carcinoma led to a complete regression of the ascites (Table II) . The same applies for solid tumors after injection of Ehrlich carcinoma cells i.m. (Table II) .
-----------------------------------------------------------------------------------------------------Molecular weights of protein bands in gel electrophoresis Accession Mass (Da) Description -----------------------------------------------------------------------------------------------------
When these animals, cured by HAP injection of their tumor disease, were challenged by repeated tumor transplantation, tumors did not grow, even if the cell number Table II . Effect of hemoglobin-associated proteins (HAP) on survival of mice with transplanted Ehrlich carcinoma. 
Significant differences between the groups 1 vs 2, and 1 vs 3. b Significant differences between the groups 4 vs 5, and 4 vs 6. NS, not significant. Each group contained 10 animals.
- (Fig. 8) . The follow-up observation of the animals continued for a year and post mortem examination did not reveal any signs of tumor growth.
Discussion
In the present study, we analyzed serum proteins of mice bearing Ehrlich carcinoma cells and compared them with mice without tumors. We found that hemoglobin associated with serum proteins of tumor-bearing animals that had a molecular weight of 300 kDa. The association included proteins having lower molecular weights of 15, 65, 68 and 100 kDa, respectively (hemoglobin-α, homologue of α-fetoprotein (AFP), serum albumin, and haptoglobin). While these complexes did not break up in column chromatography, they were dissociated in sample buffer containing 2-mercaptoethanol. Haptoglobin is known to form various high molecular weight complexes (22) . In normal blood serum of mice, hemoglobin did not form a complex with haptoglobin, because haptoglobin is only present in serum of tumor-bearing mice. This result is consistent with observations that specific proteins are solely present in plasma of tumor-bearing mice, e.g., haptoglobin, proteosome subunits, fetuin-B, 14-3-3 ζ, MAGE-B4 antigen and others (23) . In healthy mice, prevalent protein bands were found at 15, 30, and 45 kDa, which represent monomeric, dimeric and trimeric hemoglobin (24) . This indicates that not a single protein but associations of proteins might reveal biological activity. These results extend our previous studies on complex formation among serum proteins (7, 25) . We speculate that the different complex formations are due to changes in protein glycosylation during tumor growth. Protein glycosylation is important for the charge and spatial structure of protein, and, hence, for their interaction with each other. On the other hand, large molecular complexes are unlikely to be formed in blood serum, because they might disturb blood flow characteristics and physiology. Therefore, it is possible that protein complexes are formed between intracellular proteins (when they appear in blood serum after tumor cell destruction) and constitutive blood serum proteins in tumor-bearing but not in healthy mice. The most significant protein in terms of amount in blood is hemoglobin (26) . Therefore, it can be assumed that protein associations are formed with hemoglobin.
Injection of HAP to animals with transplanted Ehrlich carcinoma caused tumor regression without recurrences or metastases. HAP led to an induction of apoptosis in tumor cells. However, it is still not clear, which of the proteins are responsible for the anti-tumor effect. Humoral factors in mouse blood serum may account for the observed tumor progression (8, 25) .
It is well known that blood serum contains proteins such as haptoglobins, which form associations with hemoglobin. These associations alter hemoglobin metabolism pathways and the formation of tissue peptide pools, especially in injured tissues and organs (17) . Differences in hemoglobin metabolism of healthy and tumor-bearing animals have to be considered as well. A differential hemoglobin metabolism may be associated with post-translational modifications such as altered protein glycosylation patterns in tumor-bearing organisms. This may result in a different interaction of proteins (7) , and protein associations formed in healthy subjects may differ from those in tumor-bearing animals.
We found hemoglobin associated with a homologue to AFP by means of MALDI-TOF. AFP is able to induce apoptosis in tumor cells (27, 28) . The molecular mechanisms are at least partly elucidated. AFP-mediated apoptosis signals bypass Fas-dependent and tumor necrosis factor receptordependent signaling routes and lead to cytochrome c release, cytochrome c/dATP-mediated apoptosome complex formation, and caspase-3 and -9 activation (27, 29) . Furthermore, AFP interacts with X-linked inhibitor of apoptosis protein (XIAP) and blocks the binding of XIAP to caspase-3 (30) . XIAP suppresses caspase-3 activity. We speculate that one of the humoral factors leading to tumor regression upon HAP injection in our study may be a complex of hemoglobin and the AFP homologue identified. Another mechanism independent from the apoptosis-inducing effects is the stimulation of anti-tumor immune response. AFP enhances the dendritic-cell-mediated immune reaction of T-lymphocytes against tumor cells (31, 32) . It is intriguing that AFP isolated from human cord serum has been shown to inhibit the growth of human hepatocarcinoma cells (33) . This approach is comparable to ours and speaks for our hypothesis.
Whether complexes of hemoglobin with other serum proteins also play a role in suppression of tumor growth requires further investigation. Hemoglobin-haptoglobin complexes have been described to induce apoptosis of hepatocarcinoma cells (34) . An anti-tumor effect in our Ehrlich carcinoma model can, therefore, also be discussed. It is also possible that hemoglobin itself contributes to anti-tumor effects, since hemoglobin can mediate cytotoxicity and apoptosis towards tumor cells in a fashion similar to tumor necrosis factor-α (35) .
The phenomenon observed by us in mice with i.p. or i.m. transplanted Ehrlich carcinoma requires extended studies in other experimental models. This phenomenon merits further investigation in clinical settings. In analogy to chemoprevention, the concept of immunoprevention has been developed as an approach to prevent cancer based on the stimulation of the immune system before tumor onset (36) . It is not beyond the limits of expectations that blood serum from tumor-bearing subjects can be used not only for the treatment but also for the serological prevention of relapse of tumors (seroprevention). The full exploration of underlying mechanisms will be important to the development of novel treatment strategies in oncology.
